The Patent Finder

Netris Pharma

3 patents currently held · Updated Nov 20, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Apr 2035
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jun 3, 2027
    The maintenance fee for Anti-netrin-1 antibody (US 10,494,427) comes due Jun 3, 2027. Unpaid by Dec 3, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 3 of 3

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 10,494,427Anti-netrin-1 antibody
In force
 · USPTO record
In forceUSPTO record
US 11,648,309Novel ANTI-NETRIN-1 Antibody
In force
 · Medium confidence
In forceMedium confidence
US 12,162,932Combined Treatment with NETRIN-1 Interfering Drug and Immune Checkpoint Inhibitors Drugs
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 3: 1 patent in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending · 1 abandoned · 2 no status recorded

Showing 1 to 6 of 6, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
18/886,180Combined Treatment with NETRIN-1 Interfering Drug and Immune Checkpoint Inhibitors DrugsSep 16, 2024Pending
18/850,214Novel Mcl-1 inhibitor and combination of Mcl-1 and a BH3 mimetic, such as a Bcl-2 inhibitorMar 29, 2023Pending
18/122,273Mar 16, 2023No status recorded
18/291,972Netrin-1 detection, companion test and therapy based on radiationsJul 26, 2022Pending
13/696,386Antagonists of Sema3E/PlexinD1 interaction as anti-cancer agentsMay 6, 2011Abandoned
13/636,662Mar 23, 2011No status recorded
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited